Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 22, Issue 2, Pages 99-108Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2011.04.001
Keywords
Interleukin 15; Tumor therapy; Cancer; Cytokines
Categories
Funding
- Foundation for Polish Science
- EU
- European Regional Development Fund [POIG.01.01.02-00-008/08]
Ask authors/readers for more resources
Interleukin 15 participates in the development of important immune antitumor mechanisms. It activates CD8(+)T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Ra, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines. Although a clinical trial based on application of IL-15 in tumor patients has already begun, it is important to be aware of its potential side effects, including induction of autoimmunity and promotion of proliferation, survival, and dissemination of some tumor cells. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available